We speculated that the use of these drugs in synovial sarcoma may affect tumor development by further broadening and diluting the distribution of KDM2B and thus redistributing the SS18::SSX fusion oncoprotein to newly hypomethylated CpG islands, or by hypomethylating and activating the few genes that retain promoter hypermethylation as a means of silencing tumor suppressors or neoantigens recognized by the immune system. Here, KDM2B is linked to neoplasm.